Deals, Mergers and Acquisitions, and Licensing - Pharmaceutical Executive


Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

Integrating R&D Within M&As

November 1, 2010

The CEO should be able to communicate the vision of a merger—strategically, financially, operationally, and with the entire organization in mind

5 Years Later: Conatus Acquires Idun

August 2, 2010

Former Idun Pharma team buys back company from Pfizer.

Dealmaking Roundtable

May 1, 2010

A panel of bankers and industry executives discuss what's ahead in deals for 2010.

GSK Inks $1.5 Billion Collaboration Deal with Isis

March 31, 2010

Glaxo and Isis formed a billion-dollar alliance to create new RNA therapies for the rare and infectious disease segment. The key ingredient in the deal is Isis' drug discovery platform. Could it be a game changer? GSK thinks so.

Astellas' Hostile Takeover Turns Even More Hostile

March 3, 2010

The Japan-based company filed a lawsuit against OSI Pharmaceuticals for rejecting its tender offer, but will this strategy work?

Novartis Bids Big on Alcon

January 6, 2010

It's just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon.

Glaxo Vies for a Second Act in HIV

November 4, 2009

A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.

J&J Slims Down Elan Offer sans Tysabri

September 16, 2009

Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move.

GSK Signs $120M Deal to Market DMab Overseas

July 30, 2009

Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved.


Click here